Insights from CARTITUDE-4 and KarMMa-3 in R/R MM

Opinion
Video

Experts on multiple myeloma provide their impressions of the CARTITUDE-4 and KarMMa-3 studies, which led to the approval of cilta-cel and ide-cel in earlier lines of treatment for patients with relapsed/refractory disease.

Video content above is prompted by the following questions:

  • Briefly review the CARTITUDE-4 trial that led to cilta-cel’s approval in earlier lines of treatment for relapsed/refractory multiple myeloma (R/R MM).
    • Please comment on the patient population – intention-to-treat vs patients treated.
    • What was the rationale for the difference? How does it affect your interpretation of the data?
    • How did the safety outcomes compare with other CARTITUDE trials?
    • Please share your real-world experience.
  • Please review data from KarMMa-3, which led to ide-cel’s approval in earlier lines of therapy for R/R MM.
    • What are thoughts on the efficacy and safety outcomes?
    • Please share your real-world experience. 
  • How do these approvals impact the current and future treatment landscape of R/R MM?
    • How might you choose one over the other?
    • How does it address an unmet need?
Recent Videos
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD
A panel of 4 experts on multiple myeloma
Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD
Related Content